PLGA nanoparticles, 1μm
PLGA nanoparticles, 1μm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 1μm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 1μm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 1μm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
For research use only. We do not sell to patients.
- Formula: C7H12O4
- Molecular Weight:160.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
PLGA nanoparticles, 1μm loaded with Dexamethasone (HY-14648) completely inhibit the proliferation of vascular smooth muscle cells[2].
PLGA nanoparticles, 1μm can deliver various active substances including p53 plasmids, Curcumin (HY-N0005), cysteine protease inhibitors, Camptothecin (HY-16560), Doxorubicin (HY-15142A), Paclitaxel (HY-B0015), Cisplatin (HY-17394), and Rapamycin (HY-10219), enhance drug accumulation in multiple tumor and smooth muscle cells, and prolong the duration of action[2].
PLGA nanoparticles, 1μm show a slower initial in vitro degradation rate than 0.1 μm 50:50 PLGA nanoparticles, but a faster rate than 10 μm 50:50 PLGA microparticles; comparable degradation rates are observed for all three in the late stage of degradation[3].
PLGA nanoparticles, 1μm exhibit stronger bioadhesion to inflamed colonic mucosa than PLGA microspheres with a size of 10 μm, while PLGA nanoparticles with a smaller size (0.1 μm) show the strongest bioadhesion[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 160.17
-
Formula C7H12O4
-
SMILES
CC(C)C(OCC(OC)=O)=O.[x].[y]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Chiu HI, et al. Cytotoxicity of targeted PLGA nanoparticles: a systematic review. RSC advances. 2021 Mar 01;11(16):9433-9449. [Content Brief]
[2]. Acharya S. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Advanced drug delivery reviews. 2011 Mar 18;63(3):170-83. [Content Brief]
[3]. Bala I, et al. PLGA nanoparticles in drug delivery: the state of the art. Critical reviews in therapeutic drug carrier systems. 2004;21(5):387-422. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)